Shoko Onuma, Hirokazu Honda, Yasuna Kobayashi, Toshinori Yamamoto, Tetsuo Michihata, Keigo Shibagaki, Toshitaka Yuza, Keiichi Hirao, Naohisa Tomosugi, Takanori Shibata
Continuous erythropoietin receptor activator (CERA) and darbepoetin-α (DA) might differently affect iron metabolism and erythropoiesis in patients on hemodialysis (HD). This prospective study examined a cohort of patients on HD who had received either intravenous CERA every 2 or 4 weeks (N = 25) or DA once each week (N = 47). Blood was sampled before HD sessions on days 0, 2, 4, 7 and 14, and on days 0, 3, 5, 7 and 14 from patients who were injected with ESA at the beginning and end of the dialysis week, respectively...
December 2015: Therapeutic Apheresis and Dialysis